# Can organs be separated at Wellness Clinics America?

> Wellness Clinics America examines how semaglutide trial outcomes cross organ boundaries, from kidney composites to liver tissue and diabetic eye complications.

A kidney result can count cardiovascular deaths. A liver improvement can depend on what happens to another tissue feature. Wellness becomes harder to divide into departments.

## Adults in STEP 5

The [STEP 5 semaglutide trial reported sustained mean weight reduction over 104 weeks](https://pubmed.ncbi.nlm.nih.gov/36216945/), significantly greater than placebo, in adults with overweight or obesity. A body-weight result concerns the body as a whole. The organ headings that follow seem tidier, until their outcomes begin crossing those divisions.

I admire the time spent on the question. A result followed for two years has a different interest from the excitement around an early change, although an average still leaves individual experiences out of sight. The persistence of the result is impressive. The clinical findings that a weight measurement cannot describe deserve just as much attention.

The earlier [STEP 1 trial enrolled 1,961 adults with overweight or obesity without diabetes](https://pubmed.ncbi.nlm.nih.gov/33567185/). Mean body-weight change from baseline to week 68 was -14.9% with semaglutide and -2.4% with placebo. Those are substantial findings about the people studied. Wellness, as an ambition, asks how those organ results connect. A collection of favourable findings cannot establish that every part of the body improved together.

## Where organ outcomes overlap

The [primary kidney composite in FLOW](https://pubmed.ncbi.nlm.nih.gov/38785209/) included kidney failure, at least a 50% decline in eGFR, or death from kidney or cardiovascular causes. A cardiovascular death can therefore contribute to what is reported as a kidney outcome. That detail disrupts the neat division into organs that I expected from the trial’s subject.

The [ESSENCE liver trial required biopsy-confirmed MASH with stage 2-3 fibrosis](https://pubmed.ncbi.nlm.nih.gov/40305708/). Its [tissue endpoints paired resolution of steatohepatitis with no worsening fibrosis, and fibrosis improvement with no worsening steatohepatitis](https://pubmed.ncbi.nlm.nih.gov/40305708/). Even inside one organ, improvement has a neighbouring feature to answer to. I enjoy how these reports complicate wellness through overlapping consequences, even before any attempt to give each organ a score.

## The study rooms

[Heart outcomes](/heart) brings together cardiovascular events, an eye-complication finding and the symptoms of a specific form of heart failure. The eye finding reaches beyond the organ in the page’s name.

[Kidney disease](/kidney) concentrates on FLOW and the cardiovascular component within its kidney composite. [Liver biopsies](/liver) moves into tissue, where resolution of steatohepatitis without worsening fibrosis and fibrosis improvement without worsening steatohepatitis receive separate tests.

[Alcohol use disorder](/alcohol) has a much smaller human trial and an unusually concrete laboratory task. It deserves its own room, away from the weight-loss results that could otherwise overwhelm it. That page also marks a limit: a separate trial does not establish how drinking, weight and organ outcomes change together.

## Tolerability

Treatment difficulties also cross the tidy organ headings. The [dedicated safety review describes predominantly mild-to-moderate, transient gastrointestinal effects and an increased risk of biliary disease](https://pubmed.ncbi.nlm.nih.gov/34305810/), while judging the overall risk-benefit profile favourably in type 2 diabetes. That favourable judgement retains both its type 2 diabetes setting and its cautions.

The [cardiovascular page](/heart) considers an especially awkward pairing: [a beneficial cardiovascular result alongside more diabetic-retinopathy complications in SUSTAIN-6](https://pubmed.ncbi.nlm.nih.gov/27633186/). I think a broad account of wellness has to make room for that discomfort.

---

Wellness Clinics America is my research reading room, where published research gets a closer look at its participants; this is not a clinic or a business, and none of it is medical advice.